Imaging in Stem Cell Transplant and Cell-based Therapy

(Nancy Kaufman) #1

100



  1. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R.  Value of FDG PET in the
    assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199–204.

  2. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma.
    Br J Haematol. 2012;159:499–513.

  3. Avril N, Propper D.  Functional PET imaging in cancer drug development. Future Oncol.
    2007;3:215–28.

  4. Laforest R, Liu X.  Image quality with non-standard nuclides in PET.  Q J  Nucl Med Mol
    Imaging. 2008;52:151–8.

  5. Cejka D, Kuntner C, Preusser M, Fritzer-Szekeres M, Fueger BJ, Strommer S, et  al. FDG
    uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor
    everolimus in vivo. Br J Cancer. 2009;100:1739–45.

  6. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment
    response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with
    [18F] fluorothymidine positron emission tomography: a pilot study. J  Clin Oncol. 2007;25:
    4714–21.

  7. Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, et al. Antitumor and
    antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung
    cancer model. BMC Cancer. 2010;10:188.

  8. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, et al. Antitumor and antivascular
    effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67:9337–45.

  9. Leyton J, Alao JP, Da CM, Stavropoulou AV, Latigo JR, Perumal M, et al. In vivo biological
    activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluo-
    rothymidine positron emission tomography. Cancer Res. 2006;66:7621–9.

  10. Pollok KE, Lahn M, Enas N, McNulty A, Graff J, Cai S, et al. In vivo measurements of tumor
    metabolism and growth after administration of enzastaurin using small animal FDG positron
    emission tomography. J Oncol. 2009;2009:596560.

  11. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic
    imaging. Semin Nucl Med. 2004;34:122–33.


T.K. Garg and T. Pandey
Free download pdf